A novel long-term prediction model showed promise at estimating the risk for dying of prostate cancer, an analysis published in Annals of Internal Medicine indicated.“We have developed a tool that can ...

Prostate cancer is the second-leading cause of cancer death in American men. About 1 in 8 men will be diagnosed with prostate ...

People with localized prostate cancer treated according to guidelines developed by an international panel of doctors are more likely to die of something other than the disease, new research shows. A ...

Men diagnosed with nonmetastatic low- and intermediate-risk prostate cancer up to 6 times more likely to die of other causes. HealthDay News — Men with nonmetastatic prostate cancer receiving ...

An individual-patient meta-analysis sheds light on the optimal duration of androgen deprivation therapy in men with prostate cancer on definitive radiotherapy.

A new combination of drugs could help delay the advancement of a deadly form of prostate cancer in those with an advanced form of the disease, new research has found. The “striking” findings showed an ...

Investigators evaluated the benefit of leuprorelin immediately after radical prostatectomy for prostate cancer in patients ...

Cancer survival in the U.S. has climbed to 70%, reflecting major advances in treatment, early detection and personalized care ...

A research team from the Department of Surgery and the Department of Medicine, School of Clinical Medicine, LKS Faculty of ...

The phase 3 NRG GU-005 trial did not show a DFS benefit for SBRT vs IMRT in intermediate-risk prostate cancer, but SBRT decreased rectal toxicity. Stereotactic body radiation therapy (SBRT) preserves ...